Oslo, Norway – BASF has announced the launch of Accelon™ absorption accelerating technology. It’s been developed as a breakthrough solution to the bioavailability challenge of today’s omega-3 supplements.
Results from clinical studies showing significantly increased absorption with Accelon™ will be presented at the GOED Exchange 2018, which is taking place in Seattle, Washington from February 6 through 8.
According to a press release, Accelon™ delivers a minimum of four times better absorption of omega-3 in comparison to other market-leading high concentrate omega-3 products. This results in a higher delivery of EPA and DHA to cells throughout the body. Accelon™ therefore represents a highly distinct and relevant innovation for the omega-3 supplements category, setting new standards for absorption.
“The bioavailability topic is particularly important because poorly absorbed products, sometimes compounded by low potency, are likely to have limited benefits,” says Øyvind Ihle, Head of Global Omega-3 Nutrition at BASF. “Consumers taking their supplements in good faith risk not enjoying the full range of benefits they are hoping and paying for.”
The benefits of omega-3s have attracted much debate. As we reported here, The Journal of the American Medical Association (JAMA) recently published a study that questioned the supposed benefits of omega-3 fatty acids for cardiovascular health.
Shortly after that study was published, the Natural Products Association (NPA) responded, saying that the U.S. Food and Drug Administration (FDA) did not agree with the conclusion of the study.
According to Dr. Daniel Fabricant, president and CEO of the NPA, the FDA has approved a qualified health claim on omega-3s for cardiovascular disease and has already approved prescription medication for fish oil. He added, “We continue to believe in the strong body of evidence that omega-3 fatty acids provide a positive nutritional supplement for millions of Americans” who do not consume enough seafood.
The global Omega-3 ingredients market could be worth over $4 billion by 2022, according to Global Market Insights.
BASF is a Platinum Sponsor at GOED Exchange 2018, where the “Clarifying the Controversies in the Omega-3 Industry” session will explore the comparative bioavailability of different chemical forms as well as bioavailability improvements from new technologies, concluding with a look at the world of bioavailability marketing and claims. The session will be completed by Adam Ismail, GOED Executive Director, who explores the use of ‘bioavailability’ as an omega-3 marketing theme, the accuracy of product claims and some of the regulatory and ethical challenges associated with them.
Related stories: Adam Ismail Leaving GOED